Canada markets close in 3 hours 8 minutes

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3050+0.0250 (+1.95%)
As of 12:45PM EDT. Market open.
Sign in to post a message.
  • F
    Farmer
    In looking at their poster on the long-waited natural progression study with Vanderbilt, they only reported region-of-interest QSM results. The QSM is a biomarker of iron accumulation. In nowhere they mentioned clinical endpoints. The QSM is at most a mechanistic endpoint. The intervention must show an effect on this endpoint. Otherwise all bets are off. Suppose that's the case, i.e. positive on QSM, FDA will still want to see efficacy on clinical endpoints (symptoms, et al. ....). They have a long way to go.
  • j
    jac
    no news, no messages I am wondering what is the under line of this company?
  • A
    Archimedes
    Alterity (ATHE) has huge upside potential. Accordingly, I am holding fast on my relatively large position. I don't really need overly frequent news updates to bolster my confidence in their science & technology... I absolutely love their innovative patented IP. GLTA!
  • B
    Barry
    Check out today's Endpoints News lead article about Eli Lilly's actions and plans in terms of their announced partnership with Lycia Therapeutics. Perhaps they and Lyrica's CEO are familiar with ATHE and their small molecule drugs seeing as Dr. Sinclair's US office is in San Francisco too. It sure would be fantastic if their clinical ( & secret) targets to evaluate included ATHE 434 & PBT2 among others. No worries, Dr. Sinclair is on the case and all over this great opportunity!?
  • N
    N
    1.56M volume and a spike to 1.39!! Any news? Rumor?
  • e
    ed
    ATHE will start seeing more buy ratings in the coming months
  • N
    N
    Why is this s#*& rolling downhill today?
  • E
    Eric
    New
    Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
    -August 4, 2021
    -https://alteritytherapeutics.com/investor-centre/news/2021/08/04/alterity-announces-new-us-patent-to-expand-its-portfolio-of-compounds-for-neurodegenerative-diseases-including-alzheimers-and-parkinsons/
  • E
    End2War
    Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds

    for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s



    Composition of Matter Patent Covers More than 80 Novel Compounds



    MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 August 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity’s patent application No. 17/239,375. The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer’s and Parkinson’s.



    The patent, entitled “Compounds for and Methods of Treating Diseases”, covers more than 80 novel compounds and underwent prioritized examination by the USPTO. Together with the recent grant of Alterity’s US patent No. 10,941,143 for claims on a separate group of more than 150 novel compounds, Alterity is in a strong position with respect to its iron chaperone technology to address neurodegeneration. This position was further exemplified by the absence of any novelty or inventiveness objections during the course of prosecution.



    “As the scientific evidence implicating excess brain iron in neurodegeneration accumlates, our in-house research team continues to discover novel compounds that address this important target,” said Alterity Chief Executive Officer David Stamler, M.D. “The structural backbone illustrated in this new patent provides a larger foundation for small molecule drug candidates to attack this source of neuropathology. As we advance our lead clinical asset ATH434 into a Phase 2 clinical trial later this year, we look forward to identifying new drug candidates to add to our pipeline and address several critical diseases.”



    The notice of allowance means that the USPTO would issue the patent after certain administrative steps have been completed. The patent will confer on Alterity approximately 20 years of exclusivity over the the compounds claimed in the patent, thus providing a strong basis for drug development and commercialization in neurodegenerative diseases including the Company’s first indication Multiple System Atrophy as well as Parkinson’s Disease and Alzheimer’s Disease.
  • N
    N
    Nothing, no news can hold this stock.. Need progress and updates on Phase 2 of. ATH434 and movement on PBT2. Otherwise, it is just day traders skimming money off of long term investors.
  • e
    ed
    looks like ATHE is on the rebound. $2. seems realistic by start of phase 2 given the $4. price target. 45% in potential gains to that point. NOW is the time to pull the trigger.
  • N
    Nio Man
    I have been buying more shares on any dip for the last 2 weeks, holding 15k shares long and strong.
    The hedgies doubled down on their short positions, I am not selling until this is over $5.
  • E
    Eleanor
    The news is great! That patent gives them rights to their work. Proprietary=$$$

    "The patent will give Alterity 20 years of exclusivity over the compounds claimed in the patent, thus providing a strong basis for drug development and commercialization in neurodegenerative diseases including the company's first indication Multiple System Atrophy as well as Parkinson's Disease and Alzheimer's Disease.
  • e
    ed
    @Barry to be honest I could NEVER devote 17years into any stock that's not giving back major gains.
    ATHE 434 looks as if it could be the holy grail everyone is looking for. imo ATHE is starting to trend to the upside. continue to hang on like the trooper you are and reap the rewards you truly deserve. God speed
  • N
    Nathan Siva
    Alterity Therapeutics Limited (ASX:ATH) just published price sensitive news:

    New US Patent Expands Neurodegeneration Treatment Portfolio

    https://hotcopper.com.au/threads/ann-new-us-patent-expands-neurodegeneration-treatment-portfolio.6202688/?source=email
  • N
    Nio Man
    I am not selling and I bought another 300 shares today
  • F
    Francesco
    Notice of Allowance for Alterity's patent application No. 17/239,375. The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's.
  • F
    Francesco
    Loading up before it's too late !!